Published in BMC Clin Pathol on October 10, 2013
A fate worse than death: apoptosis as an oncogenic process. Nat Rev Cancer (2016) 1.01
A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer. EBioMedicine (2014) 0.91
Clinicopathologic Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer. J Pathol Transl Med (2016) 0.75
Expression analysis and association of RBBP6 with apoptosis in colon cancers. J Mol Histol (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med (2011) 4.68
The intestinal stem cell. Genes Dev (2008) 4.21
Inhibition of apoptosis during development of colorectal cancer. Cancer Res (1995) 2.77
Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat (2011) 1.87
Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol (2008) 1.79
Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer (1996) 1.56
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol (2004) 1.41
Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res (1995) 1.19
Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer (2005) 1.12
Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res (1999) 1.10
Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol (2003) 1.08
The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum (2005) 1.01
Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest (2001) 1.01
Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer (1997) 0.99
Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Jpn J Cancer Res (1999) 0.98
Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res (1999) 0.97
Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression. J Gastroenterol Hepatol (2002) 0.96
Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res (1996) 0.95
Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas. Histopathology (2004) 0.95
The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer (2006) 0.91
High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. Br J Cancer (2013) 0.91
Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology (2003) 0.90
M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med (2000) 0.89
Number of apoptotic cells as a prognostic marker in invasive breast cancer. Br J Cancer (2000) 0.88
KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol (2011) 0.88
Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival. J Pathol (2001) 0.84
Immunoexpression of inhibitors of apoptosis proteins and their antagonist SMAC/DIABLO in colorectal carcinoma: correlation with apoptotic index, cellular proliferation and prognosis. Oncol Rep (2009) 0.84
Apoptotic activity is increased in parallel with the metaplasia-dysplasia-carcinoma sequence of the bronchial epithelium. Br J Cancer (1999) 0.82
The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma. Cancer Lett (1999) 0.82
bcl-2 Expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol (2001) 0.82
Apoptosis and its correlation with proliferative activity in rectal cancer. J Surg Oncol (2002) 0.81
Apoptosis in relation to proliferating cell nuclear antigen and Dukes' stage in colorectal adenocarcinoma. Int J Oncol (1999) 0.81
Fas-mediated pathway and apoptosis in normal, hyperplastic, and neoplastic endometrium. Gynecol Oncol (2003) 0.78
24 hours in the life of HIV-1 in a T cell line. PLoS Pathog (2013) 1.89
Eye development: a view from the retina pigmented epithelium. Bioessays (2004) 1.79
Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol (2004) 1.68
Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005. Enferm Infecc Microbiol Clin (2011) 1.43
Imaging findings in ulnar-sided wrist impaction syndromes. Radiographics (2002) 1.40
The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn (2011) 1.40
Percutaneous tibial nerve stimulation in treatment of overactive bladder: when should retreatment be started? Urology (2011) 1.39
OTX2 activates the molecular network underlying retina pigment epithelium differentiation. J Biol Chem (2003) 1.36
Analysis of HIV-1 expression level and sense of transcription by high-throughput sequencing of the infected cell. J Virol (2011) 1.25
In vitro whole-genome analysis identifies a susceptibility locus for HIV-1. PLoS Biol (2008) 1.22
New cutaneous toxicities with generic docetaxel: are the excipients guilty? Support Care Cancer (2014) 1.14
Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Mol Cell Neurosci (2008) 1.05
Clustering of DNA words and biological function: a proof of principle. J Theor Biol (2011) 0.98
Anatomy and MR imaging appearances of synovial plicae of the knee. Radiographics (2002) 0.97
Antiretroviral activity of ancestral TRIM5alpha. J Virol (2007) 0.97
MR imaging of ankle impingement syndromes. AJR Am J Roentgenol (2003) 0.96
Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids (2014) 0.94
Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. Eur J Cancer Prev (2013) 0.94
The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest (2010) 0.93
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral Oncol (2012) 0.92
Response to paclitaxel in a radiotherapy-induced breast angiosarcoma. Acta Oncol (2009) 0.92
Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology (2009) 0.91
Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression. Antivir Ther (2003) 0.91
Kluyvera meningitis in a newborn. Pediatr Infect Dis J (2007) 0.91
Expression of hpttg proto-oncogene in lymphoid neoplasias. Oncogene (2002) 0.90
The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal (2012) 0.90
Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol (2003) 0.89
Prognostic implications of emergency admission and delays in patients with breast cancer. Support Care Cancer (2008) 0.89
The NK-1 receptor: a new target in cancer therapy. Curr Drug Targets (2011) 0.88
Update on insulin therapy for type 2 diabetes. J Clin Endocrinol Metab (2012) 0.88
NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs (2007) 0.88
Role of gene methylation in antitumor immune response: implication for tumor progression. Cancers (Basel) (2011) 0.87
Detection methods predict differences in biology and survival in breast cancer patients. BMC Cancer (2012) 0.87
High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol (2003) 0.87
Simultaneous chromophobe renal cell carcinoma and squamous renal cell carcinoma. Diagn Pathol (2007) 0.87
Unique spectrum of activity of prosimian TRIM5alpha against exogenous and endogenous retroviruses. J Virol (2011) 0.87
Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas. Histopathology (2010) 0.86
A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol (2006) 0.85
Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci (2010) 0.85
Involvement of substance P and the NK-1 receptor in cancer progression. Peptides (2013) 0.84
Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf (2014) 0.84
Genomic determinants of the efficiency of internal ribosomal entry sites of viral and cellular origin. Nucleic Acids Res (2008) 0.83
Undulated short-tail deletion mutation in the mouse ablates Pax1 and leads to ectopic activation of neighboring Nkx2-2 in domains that normally express Pax1. Genetics (2003) 0.83
Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin. Clin Transl Oncol (2012) 0.83
Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov Med (2010) 0.83
Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. PLoS One (2009) 0.82
Consequences of major accidents: assessing the number of injured people. J Hazard Mater (2005) 0.82
The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Invest New Drugs (2010) 0.82
Regulation of clusterin expression in human cancer via DNA methylation. Tumour Biol (2009) 0.81
Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci (2007) 0.81
Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci (2005) 0.81
New drug therapies for multiple sclerosis. Curr Opin Neurol (2010) 0.81
Mapping of CGRP in the alpaca (Lama pacos) brainstem. J Chem Neuroanat (2008) 0.80
Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. Int J Oncol (2013) 0.80
Beneficial effects of vasodilators in preventing severe acute pancreatitis shock. Pancreas (2006) 0.80
A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res (2009) 0.80
Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain? Clin Transl Oncol (2012) 0.79
Solitary colonic polypoid ganglioneuroma. Diagn Pathol (2008) 0.79
Pattern of expression of CXCR4 and adhesion molecules by human CD34+ cells from different sources: role in homing efficiency in NOD/SCID mice. Haematologica (2004) 0.79
Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients? BMC Cancer (2012) 0.79
Saline infusion through the pancreatic duct leads to changes in calcium homeostasis similar to those observed in acute pancreatitis. Dig Dis Sci (2008) 0.79
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer (2013) 0.79
Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08). Eur J Public Health (2011) 0.78
Endotherapia: a new frontier in the treatment of multiple sclerosis and other chronic diseases. Discov Med (2010) 0.78
Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation. Head Neck (2010) 0.78
GEMSP exerts a myelin-protecting role in the rat optic nerve. Neurol Res (2013) 0.78
Diversity of mosquitoes and the aquatic insects associated with their oviposition sites along the Pacific coast of Mexico. Parasit Vectors (2014) 0.78
The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile. Peptides (2010) 0.78
Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. Leuk Lymphoma (2011) 0.78
A new drug candidate (GEMSP) for multiple sclerosis. Curr Med Chem (2009) 0.78
Circulating antibodies directed against "polycyclic aromatic hydrocarbon-like" structures in the sera of cancer patients. Cancer Epidemiol (2009) 0.78
Presentation of Hodgkin's lymphoma with Ophelia syndrome. J Clin Oncol (2007) 0.77
Galanin receptor/neuropeptide y receptor interactions in the central nervous system. Curr Protein Pept Sci (2014) 0.77
Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf (2013) 0.77
The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. Cancers (Basel) (2010) 0.77
Mapping of alpha-neo-endorphin- and neurokinin B-immunoreactivity in the human brainstem. Brain Struct Funct (2012) 0.76
The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides (2012) 0.76
NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. Expert Opin Ther Pat (2012) 0.76
Collet-Sicard syndrome as an initial presentation of prostate cancer: a case report. J Med Case Rep (2011) 0.76
Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. Med Clin (Barc) (2008) 0.76
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study. Eur J Cancer (2005) 0.76
Relationship between plasma levels of soluble CD40L and insulin sensitivity and insulin secretion status in non-diabetic dyslipidemic patients. Diabetes Res Clin Pract (2007) 0.76
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. Cancer Chemother Pharmacol (2003) 0.76
Clinical significance of langerhans cells in squamous cell carcinoma of the larynx. J Oncol (2012) 0.76